These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 33601052)

  • 21. Novel epithelial cell adhesion molecule antibody conjugated polyethyleneimine-capped gold nanoparticles for enhanced and targeted small interfering RNA delivery to retinoblastoma cells.
    Mitra M; Kandalam M; Rangasamy J; Shankar B; Maheswari UK; Swaminathan S; Krishnakumar S
    Mol Vis; 2013; 19():1029-38. PubMed ID: 23687439
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ligand Conjugated Multimeric siRNAs Enable Enhanced Uptake and Multiplexed Gene Silencing.
    Brown JM; Dahlman JE; Neuman KK; Prata CAH; Krampert MC; Hadwiger PM; Vornlocher HP
    Nucleic Acid Ther; 2019 Oct; 29(5):231-244. PubMed ID: 31393218
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Engineered ionizable lipid siRNA conjugates enhance endosomal escape but induce toxicity in vivo.
    Biscans A; Ly S; McHugh N; Cooper DA; Khvorova A
    J Control Release; 2022 Sep; 349():831-843. PubMed ID: 35917865
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transcriptional gene silencing of HPV16 E6/E7 induces growth inhibition via apoptosis in vitro and in vivo.
    Zhou J; Peng C; Li B; Wang F; Zhou C; Hong D; Ye F; Cheng X; Lü W; Xie X
    Gynecol Oncol; 2012 Feb; 124(2):296-302. PubMed ID: 22056554
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs.
    Aigner A
    J Biotechnol; 2006 Jun; 124(1):12-25. PubMed ID: 16413079
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic silencing of KRAS using systemically delivered siRNAs.
    Pecot CV; Wu SY; Bellister S; Filant J; Rupaimoole R; Hisamatsu T; Bhattacharya R; Maharaj A; Azam S; Rodriguez-Aguayo C; Nagaraja AS; Morelli MP; Gharpure KM; Waugh TA; Gonzalez-Villasana V; Zand B; Dalton HJ; Kopetz S; Lopez-Berestein G; Ellis LM; Sood AK
    Mol Cancer Ther; 2014 Dec; 13(12):2876-85. PubMed ID: 25281617
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nanovehicle-based Small Interfering RNA (siRNA) Delivery for Therapeutic Purposes: A New Molecular Approach in Pharmacogenomics.
    Akhtari J; Tafazoli A; Mehrad-Majd H; Mahrooz A
    Curr Clin Pharmacol; 2018; 13(3):173-182. PubMed ID: 29992895
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor Selective Silencing Using an RNAi-Conjugated Polymeric Nanopharmaceutical.
    Svenson S; Case RI; Cole RO; Hwang J; Kabir SR; Lazarus D; Lim Soo P; Ng PS; Peters C; Shum P; Sweryda-Krawiec B; Tripathi S; van der Poll D; Eliasof S
    Mol Pharm; 2016 Mar; 13(3):737-47. PubMed ID: 26835715
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic Delivery of Folate-PEG siRNA Lipopolyplexes with Enhanced Intracellular Stability for In Vivo Gene Silencing in Leukemia.
    Lee DJ; Kessel E; Lehto T; Liu X; Yoshinaga N; Padari K; Chen YC; Kempter S; Uchida S; Rädler JO; Pooga M; Sheu MT; Kataoka K; Wagner E
    Bioconjug Chem; 2017 Sep; 28(9):2393-2409. PubMed ID: 28772071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors.
    Ganesh S; Iyer AK; Morrissey DV; Amiji MM
    Biomaterials; 2013 Apr; 34(13):3489-502. PubMed ID: 23410679
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted Delivery with Imaging Assessment of siRNA Expressing Nanocassettes into Cancer.
    Chen W; Yang L
    Methods Mol Biol; 2016; 1372():49-59. PubMed ID: 26530914
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CXCR4-targeted modular peptide carriers for efficient anti-VEGF siRNA delivery.
    Egorova A; Shubina A; Sokolov D; Selkov S; Baranov V; Kiselev A
    Int J Pharm; 2016 Dec; 515(1-2):431-440. PubMed ID: 27789364
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Triton X-100-Modified Adenosine Triphosphate-Responsive siRNA Delivery Agent for Antitumor Therapy.
    Fan X; Zhao X; Su W; Tang X
    Mol Pharm; 2020 Oct; 17(10):3696-3708. PubMed ID: 32803981
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor-specific delivery of therapeutic siRNAs by anti-EGFR immunonanoparticles.
    Kim JS; Kim MW; Kang SJ; Jeong HY; Park SI; Lee YK; Kim HS; Kim KS; Park YS
    Int J Nanomedicine; 2018; 13():4817-4830. PubMed ID: 30214190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Journey of siRNA: Clinical Developments and Targeted Delivery.
    Nikam RR; Gore KR
    Nucleic Acid Ther; 2018 Aug; 28(4):209-224. PubMed ID: 29584585
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systematic chemical modifications of single stranded siRNAs significantly improved CTNNB1 mRNA silencing.
    Chang W; Pei Y; Guidry EN; Zewge D; Parish CA; Sherer EC; DiMuzio J; Zhang H; South VJ; Strapps WR; Sepp-Lorenzino L; Colletti SL; Stanton MG
    Bioorg Med Chem Lett; 2016 Sep; 26(18):4513-4517. PubMed ID: 27503684
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bioinspired tumor-homing nanoplatform for co-delivery of paclitaxel and siRNA-E7 to HPV-related cervical malignancies for synergistic therapy.
    Xu C; Liu W; Hu Y; Li W; Di W
    Theranostics; 2020; 10(7):3325-3339. PubMed ID: 32194871
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles.
    Nascimento AV; Singh A; Bousbaa H; Ferreira D; Sarmento B; Amiji MM
    Acta Biomater; 2017 Jan; 47():71-80. PubMed ID: 27697601
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Wan X; Sun R; Bao Y; Zhang C; Wu Y; Gong Y
    Mol Pharm; 2021 Nov; 18(11):3990-3998. PubMed ID: 34591491
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth.
    Su Y; Yu L; Liu N; Guo Z; Wang G; Zheng J; Wei M; Wang H; Yang AG; Qin W; Wen W
    Cancer Lett; 2013 Sep; 338(2):282-91. PubMed ID: 23752065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.